Abigail Berman, MD
Radiation Oncology · Philadelphia, PANPI 1235364423
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $24,947 of the $25,050 with a category attached, or 99.6%. AstraZeneca accounts for 84.8% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2021 at $16,636 and has fallen 99.5% since, to $84 in 2025. Among radiation oncology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 10 payments — averaging $2505.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$21K
- Varian Medical Systems, Inc.$4K
- AbbVie$19
Across 11 payments — averaging $81,730 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$899K
What the payments were for
- Consulting fees$24,947100%
- Food & beverage$1030%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 8 | $21,250 |
| Varian Medical Systems, Inc. | 1 | $3,782 |
| AbbVie | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$25,050 in reported general payments places this provider in the 95th percentile of 339 radiation oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other radiation oncology in Philadelphia
- Neil TaunkPhiladelphia$203K
- Wenyin ShiPhiladelphia$119K
- Kevin NeadPhiladelphia$50K
- Adam DickerPhiladelphia$46K
- Tinatin ChabrashviliPhiladelphia$39K
- Bryan PukenasPhiladelphia$36K
- Sameera KumarPhiladelphia$29K
- Joshua MeyerPhiladelphia$25K
- Michelle Alonso-BasantaPhiladelphia$23K
- Andy MinnPhiladelphia$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.